---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-059740"
form_type: "8-K"
ticker: "SYBX"
cik: "0001527599"
company_name: "SYNLOGIC, INC."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T14:54:52.776724+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Synlogic earns $2.5M milestone payment from Roche for IBD program

## Summary
- Third milestone achieved under June 2021 Roche collaboration for Synthetic Biotic in IBD.
- $2.5 million payment triggered; previous milestones in Sep 2021 and Aug 2022.
- Roche retains exclusive option to license and commercialize the candidate.
- Synlogic's Synthetic Biotics are oral, gut-restricted biotherapeutics for serious diseases.
- Mylene Perreault, VP Research, emphasizes compelling fit with IBD disease biology.

## SEC filing metadata
- accession: 0000950170-23-059740
- form_type: 8-K
- ticker: SYBX
- cik: 0001527599
- company_name: SYNLOGIC, INC.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527599/000095017023059740/0000950170-23-059740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527599/000095017023059740/sybx-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-059740
- JSON: https://secwatch.observer/filing/0000950170-23-059740.json
- Plain text: https://secwatch.observer/filing/0000950170-23-059740.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.